[go: up one dir, main page]

AR132818A1 - Compuestos para la degradación de la cinasa egfr - Google Patents

Compuestos para la degradación de la cinasa egfr

Info

Publication number
AR132818A1
AR132818A1 ARP240101375A ARP240101375A AR132818A1 AR 132818 A1 AR132818 A1 AR 132818A1 AR P240101375 A ARP240101375 A AR P240101375A AR P240101375 A ARP240101375 A AR P240101375A AR 132818 A1 AR132818 A1 AR 132818A1
Authority
AR
Argentina
Prior art keywords
degradation
compounds
egfr kinase
compound
pharmaceutically acceptable
Prior art date
Application number
ARP240101375A
Other languages
English (en)
Inventor
Huaqing Liu
Bailin Lei
Yizhou Zhao
Xinzhu Qi
Guanjun Liu
Zhiwei Wang
Original Assignee
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh
Publication of AR132818A1 publication Critical patent/AR132818A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto con la fórmula (1). Una composición farmacéutica que comprende un compuesto de cualquiera de las reivindicaciones 1 - 77, o una sal, estereoisómero, tautómero, o profármaco farmacéuticamente aceptable de este, junto con un excipiente farmacéuticamente aceptable.
ARP240101375A 2023-05-31 2024-05-30 Compuestos para la degradación de la cinasa egfr AR132818A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2023097387 2023-05-31
CN2023125498 2023-10-19
CN2024090756 2024-04-30

Publications (1)

Publication Number Publication Date
AR132818A1 true AR132818A1 (es) 2025-07-30

Family

ID=91670399

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101375A AR132818A1 (es) 2023-05-31 2024-05-30 Compuestos para la degradación de la cinasa egfr

Country Status (9)

Country Link
US (1) US20240425523A1 (es)
CN (1) CN121194978A (es)
AR (1) AR132818A1 (es)
AU (1) AU2024281173A1 (es)
CO (1) CO2025018512A2 (es)
IL (1) IL324672A (es)
MX (1) MX2025013993A (es)
TW (1) TW202448898A (es)
WO (1) WO2024246838A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025214405A1 (zh) * 2024-04-09 2025-10-16 海思科医药集团股份有限公司 一种吡唑衍生物及其在医药上的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295041A1 (en) 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CN108136044B (zh) 2015-06-04 2021-08-10 阿尔维纳斯运营股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
CN108137507A (zh) 2015-07-10 2018-06-08 阿尔维纳斯股份有限公司 基于mdm2的蛋白水解调节剂和相关的使用方法
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
EP3892272B1 (en) 2016-04-22 2024-07-24 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
ES2945224T3 (es) 2016-10-11 2023-06-29 Arvinas Operations Inc Compuestos y métodos para la degradación dirigida del receptor de andrógenos
WO2018119441A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
EP3728251A1 (en) 2017-12-18 2020-10-28 F. Hoffmann-La Roche AG Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
TW201945357A (zh) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
EP3986564A1 (en) * 2019-06-24 2022-04-27 Boehringer Ingelheim International GmbH New macrocyclic compounds and derivatives as egfr inhibitors
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
WO2021057882A1 (zh) 2019-09-26 2021-04-01 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
PE20221724A1 (es) 2019-12-20 2022-11-04 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
AR120800A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
CN115135642B (zh) 2019-12-23 2025-03-04 缆图药品公司 Egfr突变形式的抑制剂
JP2023513854A (ja) 2020-02-18 2023-04-03 テーセウス ファーマシューティカルズ， インコーポレイテッド 大環状化合物およびその使用
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
BR112022019888A2 (pt) 2020-04-14 2022-11-22 Qilu Pharmaceutical Co Ltd Compostos tricíclicos como inibidores de egfr
WO2021216440A1 (en) 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
JP2024529415A (ja) * 2021-07-23 2024-08-06 メッドシャイン ディスカバリー インコーポレイテッド 大環状アミド化合物およびその適用
TW202330548A (zh) 2021-11-30 2023-08-01 英屬開曼群島商百濟神州有限公司 用於降解egfr激酶的化合物

Also Published As

Publication number Publication date
CO2025018512A2 (es) 2026-01-13
WO2024246838A1 (en) 2024-12-05
MX2025013993A (es) 2026-01-07
TW202448898A (zh) 2024-12-16
US20240425523A1 (en) 2024-12-26
IL324672A (en) 2026-01-01
AU2024281173A1 (en) 2025-12-04
CN121194978A (zh) 2025-12-23

Similar Documents

Publication Publication Date Title
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2024010399A (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
CO2022008171A2 (es) Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo
AR133988A1 (es) Inhibidores de ras-pi3k y usos de los mismos
AR131639A1 (es) Inhibidores de kif18a y usos de los mismos
UY39799A (es) Compuestos de pirrolil–sulfonamida
CO2021017202A2 (es) Compuestos tricíclicos
MX2024011951A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromaticos
AR128932A1 (es) Inhibidores de bcl-xl
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
AR132818A1 (es) Compuestos para la degradación de la cinasa egfr
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
AR133240A1 (es) Compuestos, composiciones y métodos
AR129185A1 (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
MX2023000926A (es) Nuevo derivado de pirazol.
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
AR132764A1 (es) Inhibidores de tyk2 y sus usos
AR128868A1 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
MX2024008745A (es) Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo.
AR063233A1 (es) Inhibidores de quinasas
AR134197A1 (es) Compuestos para el tratamiento de enfermedad renal
AR127559A1 (es) Compuestos, composiciones y métodos